Days after getting a recommendation for approval in Europe, AstraZeneca PLC has been given the green light in the US to market Fasenra (benralizumab) as a treatment for severe asthma and an alternative to GlaxoSmithKline PLC’s Nucala (mepolizumab) and Teva Pharmaceutical Industries Ltd.'s Cinqair (respizumab).
Specifically, the US Food and Drug Administration has approved Fasenra for the add-on maintenance treatment of patients with severe asthma aged 12 years and older who have an eosinophilic phenotype
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?